Patent ID: 9598734
Date: 2017-03-21
CPC Classifications: C12Q

Claim:
1. A method of predicting the responsiveness of a patient diagnosed with brain cancer, lung cancer, or lymphoma to at least one treatment for cancer comprising: i) contacting a tumor sample comprising one or more nucleic acid molecules from said patient with a device comprising at least one first single-stranded nucleic acid molecule having at least 85% sequence identity to a nucleic acid sequence that is complementary or identical to at least 15 consecutive nucleotides of hsa-miR-766_st (SEQ ID NO: 1); and ii) measuring hybridization between said one or more nucleic acid molecules from said patient and said at least one first single-stranded nucleic acid molecule of said device to detect a level of expression of hsa-miR-766_st; wherein said patient is predicted to be responsive to said least one treatment for cancer if the level of expression of hsa-miR-766_st is substantially similar to the level of expression of hsa-miR-766_st in a cell or tissue known to be responsive to said at least one treatment for cancer.